Literature DB >> 23199603

Advances in pediatric asthma in 2012: moving toward asthma prevention.

Stanley J Szefler1.   

Abstract

Last year's "Advances in pediatric asthma: moving forward" concluded the following: "Now is also the time to utilize information recorded in electronic medical records to develop innovative disease management plans that will track asthma over time and enable timely decisions on interventions in order to maintain control that can lead to disease remission and prevention." This year's summary will focus on recent advances in pediatric asthma on modifying disease activity, preventing asthma exacerbations, managing severe asthma, and risk factors for predicting and managing early asthma, as indicated in Journal of Allergy and Clinical Immunology publications in 2012. Recent reports continue to shed light on methods to improve asthma management through steps to assess disease activity, tools to standardize outcome measures in asthma, genetic markers that predict risk for asthma and appropriate treatment, and interventions that alter the early presentation of asthma to prevent progression. We are well on our way to creating a pathway around wellness in asthma care and also to use new tools to predict the risk for asthma and take steps to not only prevent asthma exacerbations but also to prevent the early manifestations of the disease and thus prevent its evolution to severe asthma.
Copyright © 2012 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23199603     DOI: 10.1016/j.jaci.2012.11.009

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  5 in total

1.  Neuroimmune semaphorin 4A as a drug and drug target for asthma.

Authors:  G Mogie; K Shanks; E H Nkyimbeng-Takwi; E Smith; E Davila; M M Lipsky; L J DeTolla; A D Keegan; S P Chapoval
Journal:  Int Immunopharmacol       Date:  2013-08-28       Impact factor: 4.932

2.  Advances in pediatric asthma in 2013: coordinating asthma care.

Authors:  Stanley J Szefler
Journal:  J Allergy Clin Immunol       Date:  2014-03       Impact factor: 10.793

Review 3.  Researching asthma across the ages: insights from the National Heart, Lung, and Blood Institute's Asthma Network.

Authors:  Michael D Cabana; Susan J Kunselman; Sharmilee M Nyenhuis; Michael E Wechsler
Journal:  J Allergy Clin Immunol       Date:  2014-01       Impact factor: 10.793

4.  Farnesol, a sesquiterpene alcohol in herbal plants, exerts anti-inflammatory and antiallergic effects on ovalbumin-sensitized and -challenged asthmatic mice.

Authors:  Chi-Mei Ku; Jin-Yuarn Lin
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-19       Impact factor: 2.629

5.  IL‑27 suppresses airway inflammation, hyperresponsiveness and remodeling via the STAT1 and STAT3 pathways in mice with allergic asthma.

Authors:  Degan Lu; Jiameng Lu; Xiaoqing Ji; Yanbo Ji; Zewen Zhang; Haiying Peng; Fei Sun; Caiqing Zhang
Journal:  Int J Mol Med       Date:  2020-05-29       Impact factor: 4.101

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.